Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy

Targeting immune evasion via immune checkpoint pathways has changed the treatment paradigm in cancer. Since CTLA-4 antibody was first approved in 2011 for treatment of metastatic melanoma, eight immune checkpoint inhibitors (ICIs) centered on PD-1 pathway blockade are approved and currently administ...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jii Bum, Kim, Hye Ryun, Ha, Sang-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Immunologists 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901707/
https://www.ncbi.nlm.nih.gov/pubmed/35291660
http://dx.doi.org/10.4110/in.2022.22.e2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901707/
https://www.ncbi.nlm.nih.gov/pubmed/35291660
http://dx.doi.org/10.4110/in.2022.22.e2

Ejemplares similares